Abstract CT226: Phase 2 study of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with head and neck squamous cell carcinoma (HNSCC) previously treated with checkpoint inhibitor
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-ct226
Abstract: BACKGROUND: FLX475 (tivumecirnon) is a selective CCR4 antagonist designed to block the recruitment of immunosuppressive regulatory T cells (Treg) into the tumor microenvironment. The FLX475-02 trial (NCT03674567) is a phase 1/2 study of FLX475 as… read more here.
Keywords: cancer; phase study; ccr4 antagonist; flx475 tivumecirnon ... See more keywords
A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Investigation"
DOI: 10.1172/jci82976
Abstract: Elevated expression of the chemokine receptor CCR4 in tumors is associated with poor prognosis in several cancers. Here, we have determined that CCR4 was highly expressed in human renal cell carcinoma (RCC) biopsies and observed… read more here.
Keywords: ccr4 antagonist; ccr4; antibody; anti ccr4 ... See more keywords